Share Name Share Symbol Market Type Share ISIN Share Description
Cello Health Plc LSE:CLL London Ordinary Share GB00B0310763 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 161.00 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Media 166.77 7.11 -0.88 183
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 161.00 GBX

Cello Health (CLL) Latest News

Real-Time news about Cello Health Plc (London Stock Exchange): 0 recent articles
More Cello Health News
Cello Health Investors    Cello Health Takeover Rumours

Cello Health (CLL) Discussions and Chat

Cello Health Forums and Chat

Date Time Title Posts
18/8/202015:24Cello - solid prospects1,087
29/1/201516:56CELLO GROUP?9
12/1/200516:17Cello or EQI?-

Add a New Thread

Cello Health (CLL) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Cello Health trades in real-time

Cello Health (CLL) Top Chat Posts

Cello Health Daily Update: Cello Health Plc is listed in the Media sector of the London Stock Exchange with ticker CLL. The last closing price for Cello Health was 161p.
Cello Health Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 0p while the 1 year low share price is currently 0p.
There are currently 113,500,683 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Cello Health Plc is £182,736,099.63.
coopstock: Why would anyone buy at 163p - when agreed price is 161p? Am I missing something?
qs99: US market recovery and economic news today, may help CLL....let's see
qs99: Having to pay full offer price....DYOR....looking for 10-15% from update key
davebowler: Cenkos- Navigating positively through disruptions Cello’s AGM statement should reassure that FY20 trading to date remains robust, underpinned by “solid” growth in net revenue in Q1/20. While Q2/20 saw certain early disruption, overall progress has been made to maintain revenues alongside effective cost controls, thus a creditable H1/20E result is expected. The 23% fall in the shares since February’s highs, appears to overly discount for the actual reality of this disruption.  Despite some disruption in Q2/20, the Cello Health division continues to perform:  Q1/20: Cello Health delivered “strong” overall net revenue and profit growth over Q1/20, benefitting from ISS’s acquisition in August 2019. On a LFL basis, excluding ISS, organic growth has been described as “good”, continuing recent momentum.  Q2/20: Commentary on trading post the COVID-19 outbreak suggests of continued progress, with new win rates being maintained, leading to a continuation of the typical six month visibility to bookings going into H2/20. This comes despite some disruption in activities requiring physical proximity (healthcare conventions, expert focus groups etc), which are being digitally delivered or have been put on hold.  Some COVID-19 benefits: New projects have arisen as result of the pandemic, with Cello Connect, the digital and creative marketing capability transferred from Signal, delivering COVID-19 related public health campaigns, while newly acquired ISS is also benefitting from new US regulatory drug approvals and FDA fillings.  Signal expected to be more impacted, but it’s far less material this year: Cello Signal generated only 16% of net revenue in Q1/20 following Connect’s transfer at the start of the year. Over Q2/20 and beyond, trading is unsurprisingly expected to be challenged by COVID-19, given certain clients are engaged in troubled sectors (eg travel, leisure), thus some delays and cancellations are expected. As such, cost control measures have, and continue to be undertaken, where necessary.  Balance sheet remains strong: Today’s update confirms Cello maintains a “solid” net cash position. This comes despite a seasonal working capital outflow in Q1/20 and is inclusive of a £0.7m payment for the final earn-out payment on Defined Health and FY19A’s £1.1m final dividend. The implies positive cash generation to date this year.  Valuation: Prior to the COVID-19 outbreak, Cello traded at a forward P/E of 16.0x in late February, a multiple we feel is merited. If Cello were to deliver a FY20E result largely consistent with FY19A, a price today of 151p p/s (+32% upside) would be fair.
coopstock: Cutting the dividend just one week after announcing the award of all those new share options for senior directors. All in this together - I don't think so. Pretty poor.
qs99: Any vague return to normality and given HNT purchase recently, IMO this will get bought out if it stays at this price. DYOR
zipstuck: As the major drug companies are being squeezed on supply chains you have to wonder how this might affect CLL
bargainbob: Poikka glad i introduced a little Fanny to the advfn boards and it boosted the share price to heights not seen before. Good luck reaching 150p
f15jcm: I bought for a new position today. With the price at 140p I figured my 17,500 shares would push the price to 12y highs, which seems to have worked.
davr0s: Who knows but I buy breakouts like this any day of the week. Shares that are going to go and make big gains have to break out first. No idea where price will end up but gotta be in the game to capture some of these
Cello Health share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
Cello Heal..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20220707 10:32:21